Drug lookup
Drug reference

Flurazepam

Long-acting benzodiazepine hypnotic · Insomnia

Also known as Flurazepam hydrochloride, Dalmane

START
15 mg PO at bedtime; short-term use only
TYPICAL MAX
30 mg at bedtime (short-term)
STOP IF
Daytime impairment, falls, or signs of dependence
WATCH
Sedation/falls, cognition (elderly), respiratory status, dependence
CDSCO approvedATC N05CD01
Dose laddermg/d
15elderly30max bedtime
Renal dose adjustmenteGFR mL/min/1.73m²
CAUTIONNo fixed adjustment; caution90

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours
30minONSET1.5hPEAK2.9d8hDURATION
ONSET
30min · absorption
PEAK
1.5h · Tmax
2.9d · metabolite t½
DURATION
8h · hypnosis
EXCRETION
Renal — metabolites
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Contraindicated (esp. 1st trimester / near term).
FDA category + note
Top interactionssee all 12
  • MethylnaltrexoneSevereTextbookG&G 14e
  • NalmefeneSevereTextbookG&G 14e
  • NaloxoneSevereTextbookG&G 14e
  • NaltrexoneSevereTextbookG&G 14e

Mechanism

Allosteric agonist at GABA-A receptor benzodiazepine site, potentiating chloride influx and producing sedation/hypnosis; active metabolites (desalkylflurazepam) prolong action.

Indications

Short-term management of insomnia

Dosing

Adult
15–30 mg PO at bedtime for short-term use (≤2–4 weeks).
Pediatric
Not recommended.
Renal adjustment
No specific adjustment; caution.
Hepatic adjustment
Reduce dose / extend interval (active metabolite accumulation).
Geriatric
Avoid (Beers criteria — fall/cognitive risk); if used 15 mg start.
Max dose
30 mg at bedtime

Pharmacokinetics

Onset
15–45 min (oral)
Peak effect
~1–2 h
Duration
Hypnotic 7–8 h; residual sedation longer
Half-life
Parent ~2.3 h; active desalkyl ~47–100 h (accumulates)
Bioavailability
Well absorbed orally
Protein binding
Active metabolite high
Metabolism
Hepatic CYP3A4 (active metabolites)
Excretion
Renal (metabolites)

Contraindications

  • Acute angle-closure glaucoma
  • Severe respiratory insufficiency / sleep apnoea
  • Myasthenia gravis
  • Pregnancy/breastfeeding
  • Hypersensitivity to benzodiazepines

Side effects

Common
Daytime drowsiness/hangoverDizzinessHeadacheAtaxia (elderly)
Serious
  • Dependence/withdrawal
  • Falls/fractures (elderly)
  • Respiratory depression (with opioids/alcohol)
  • Paradoxical agitation

Pregnancy & lactation

Pregnancy

Contraindicated (esp. 1st trimester / near term).

Lactation

Avoid breastfeeding (excreted, neonatal sedation).

Drug interactions

Methylnaltrexone
Severe
Textbook

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: G&G 14e

Nalmefene
Severe
Textbook

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: G&G 14e

Naloxone
Severe
Textbook

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: G&G 14e

Naltrexone
Severe
Textbook

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: G&G 14e

Other Cns Depressants
Severe
Textbook

Typically fatal if combined in overdose.

Use with extreme caution; avoid if possible.

Source: G&G 14e

Alfentanil
Severe
Database

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: DDInter

Benzhydrocodone
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Buprenorphine
Severe
Database

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: DDInter

Butorphanol
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Clozapine
Severe
Database

Drug interaction classified as: synergy.

Source: DDInter

Codeine
Severe
Database

Increased rates of accidental overdose and death.

Caution is advised, especially for patients with a history of drug abuse.

Source: DDInter

Dextropropoxyphene
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Ask House about Flurazepam

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20